The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Open accessAbstract
Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50-70% of malignant melanomas. Pre-clinical studies have demonstrated that the B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma-an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials. However, clinical responses to targeted anticancer therapeutics are frequently confounded by de novo or acquired resistance. Identification of resistance mechanisms in a manner that elucidates alternative 'druggable' targets may inform effective long-term treatment strategies. Here we expressed ∼600 kinase and kinase-related open reading frames (ORFs) in parallel to interrogate resistance to a selective RAF kinase inhibitor. We identified MAP3K8 (the gene encoding COT/Tpl2) as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines. COT activates ERK primarily through MEK-dependent mechanisms that do not require RAF signalling. Moreover, COT expression is associated with de novo resistance in B-RAF(V600E) cultured cell lines and acquired resistance in melanoma cells and tissue obtained from relapsing patients following treatment with MEK or RAF inhibitors. We further identify combinatorial MAPK pathway inhibition or targeting of COT kinase activity as possible therapeutic strategies for reducing MAPK pathway activation in this setting. Together, these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors have proven ineffective as single agents due to adaptive feedback re-activation of the MAPK and other signaling pathways [5–13, 38].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationSystematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,002
Raf kinases in cancer–roles and therapeutic opportunities
Maurer, G., Tarkowski, B., & Baccarini, M. (2011) · Oncogene · doi:10.1038/onc.2011.160 · Cited by 311
Kakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182721 · Cited by 277
Meyer, A. S., Miller, M. A., Gertler, F. B., & Lauffenburger, D. A. (2013) · Science Signaling · doi:10.1126/scisignal.2004155 · Cited by 283
ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?
Buscà, R., Pouysségur, J., & Lenormand, P. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00053 · Cited by 303
Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
Yancovitz, M., Litterman, A. J., Yoon, J., Ng, E., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Darvishian, F., Christos, P. J., Mazumdar, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029336 · Cited by 287
Schulz, D., Zanotelli, V. R., Fischer, J. R., Schapiro, D., Engler, S., Lun, X., Jackson, H. W., & Bodenmiller, B. (2017) · Cell Systems · doi:10.1016/j.cels.2017.12.001 · Cited by 277
A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties
Murphy, J. M., Zhang, Q., Young, S. N., Reese, M. L., Bailey, F. P., Eyers, P. A., Ungureanu, D., Hammarén, H. M., Silvennoinen, O., Varghese, L. N., et al. (2013) · Biochemical Journal · doi:10.1042/bj20131174 · Cited by 278
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Flockhart, R. J., Webster, D. E., Qu, K., Mascarenhas, N., Kovalski, J., Kretz, M., & Khavari, P. A. (2012) · Genome Research · doi:10.1101/gr.140061.112 · Cited by 277
Many ways to resistance: How melanoma cells evade targeted therapies
Kozar, I., Margue, C., Rothengatter, S., Haan, C., & Kreis, S. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.02.002 · Cited by 289
Polytherapy and Targeted Cancer Drug Resistance
Chatterjee, N., & Bivona, T. G. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.003 · Cited by 277
BRAF targeted therapy changes the treatment paradigm in melanoma
Ribas, A., & Flaherty, K. T. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.69 · Cited by 274
Self-citationPlasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3498 · Cited by 275
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T. J., Mok, S., Cass, A. A., Haynes, N. M., Kinross, K. M., Yagita∥, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 274
RetractedA Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Self-citationA multi‐colour/multi‐affinity marker set to visualize phosphoinositide dynamics in A rabidopsis
Simon, M. L. A., Platre, M. P., Assil, S., van Wijk, R., Chen, W. Y., Chory, J., Dreux, M., Munnik, T., & Jaillais, Y. (2013) · The Plant Journal · doi:10.1111/tpj.12358 · Cited by 270
Hayes, T. K., Neel, N. F., Hu, C., Gautam, P., Chénard, M., Long, B. J., Aziz, M., Kassner, M., Bryant, K. L., Pierobon, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.011 · Cited by 266
The kinome 'at large' in cancer
Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2015.18 · Cited by 268
MEK in cancer and cancer therapy
Neuzillet, C., Tijeras‐Raballand, A., de Mestier, L., Cros, J. F., Faivre, S. J., & Raymond, É. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.001 · Cited by 273
Misale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007947 · Cited by 263
Elucidating Distinct Roles for NF1 in Melanomagenesis
Maertens, O., Johnson, B., Hollstein, P., Frederick, D. T., Cooper, Z. A., Messiaen, L., Bronson, R. T., McMahon, M., Granter, S., Flaherty, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0313 · Cited by 258
Self-citationComplexity in the signaling network: insights from the use of targeted inhibitors in cancer therapyPreprint
Logue, J. S., & Morrison, D. K. (2012) · Genes & Development · doi:10.1101/gad.186965.112 · Cited by 259
Mutant BRAF Melanomas—Dependence and Resistance
Poulikakos, P. I., & Rosen, N. X. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.008 · Cited by 256
Targeting Oncogenic BRAF: Past, Present, and Future
Zaman, A., Wu, W., & Bivona, T. G. (2019) · Cancers · doi:10.3390/cancers11081197 · Cited by 252
BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
Segura, M. F., Fontanals-Cirera, B., Gaziel‐Sovran, A., Guijarro, M. V., Hanniford, D., Zhang, G., González‐Gómez, P., Morante, M., Jubierre, L., Zhang, W., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0122-t · Cited by 247
Resistance to BRAF Inhibition in Melanomas
Solit, D. B., & Rosen, N. X. (2011) · New England Journal of Medicine · doi:10.1056/nejmcibr1013704 · Cited by 243
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
Abel, E. V., Basile, K. J., Kugel, C. H., Witkiewicz, A. K., Le, K., Amaravadi, R. K., Karakousis, G. C., Xu, X., Xu, W., Schuchter, L. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65780 · Cited by 249
Targeting TGF-β Signaling for Therapeutic GainPreprint
Akhurst, R. J. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022301 · Cited by 255
Targeting the BRAF V600E Mutation in Multiple Myeloma
Andrulis, M., Lehners, N., Capper, D., Penzel, R., Heining, C., Hüellein, J., Zenz, T., von Deimling, A., Schirmacher, P., Ho, A. D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0014 · Cited by 236
Tsai, W.-B., Aiba, I., Long, Y., Lin, H., Feun, L. G., Savaraj, N., & Kuo, M. T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3605 · Cited by 235
Zimmer, L., Hillen, U., Livingstone, E., Lacouture, M. E., BUSAM, K. J., Carvajal, R. D., Egberts, F., Hauschild, A., Kashani–Sabet, M., Goldinger, S. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.1660 · Cited by 234
Self-citationTargeting tumour-supportive cellular machineries in anticancer drug development
Dobbelstein, M., & Moll, U. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4201 · Cited by 233
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Atefi, M. S., von Euw, E., Attar, N., Ng, C., Chu, C., Guo, D., Nazarian, R., Chmielowski, B., Glaspy, J. A., Comin-Anduix, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028973 · Cited by 236
Pre-clinical modeling of cutaneous melanoma
Rebecca, V. W., Somasundaram, R., & Herlyn, M. (2020) · Nature Communications · doi:10.1038/s41467-020-15546-9 · Cited by 244
β-cell–mimetic designer cells provide closed-loop glycemic control
Xie, M., Ye, H., Wang, H., Hamri, G. C., Lormeau, C., Saxena, P., Stelling, J., & Fussenegger, M. (2016) · Science · doi:10.1126/science.aaf4006 · Cited by 229
Li, Z., Ivanov, A. A., Su, R., González-Pecchi, V., Qi, Q., Liu, S., Webber, P. J., McMillan, E. A., Rusnak, L., Pham, C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14356 · Cited by 232
Ardekani, G. S., Jafarnejad, S. M., Tan, L., Saeedi, A., & Li, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047054 · Cited by 231
Haq, R., Yokoyama, S., Hawryluk, E. B., Jönsson, G. B., Frederick, D. T., McHenry, K. T., PORTER, D. A., Tran, T.-N., Love, K. T., Langer, R., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205575110 · Cited by 229
Self-citationKing, A. J., Arnone, M. R., Bleam, M. R., Moss, K. G., Yang, J., Fedorowicz, K. E., Smitheman, K. N., Erhardt, J. A., Hughes‐Earle, A., Kane-Carson, L. S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067583 · Cited by 228
Shi, H., Kong, X., Ribas, A., & Lo, R. S. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0140 · Cited by 229
Batalla, I. B., Schultze, A., Wroblewski, M., Erdmann, R., Heuser, M., Waizenegger, J. S., Riecken, K., Binder, M., Schewe, D. M., Sawall, S., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491431 · Cited by 218
Pathways and therapeutic targets in melanoma
Shtivelman, E., Davies, M. A., Hwu, P., Yang, J. C.-H., Lotem, M., Oren, M., Flaherty, K. T., & Fisher, D. E. (2014) · Oncotarget · doi:10.18632/oncotarget.1892 · Cited by 226
Self-citationTherapy for metastatic melanoma: the past, present, and future
Finn, L. E., Markovic, S. N., & Joseph, R. W. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-23 · Cited by 224
ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor
Li, D., March, M., Gutiérrez-Uzquiza, Á., Kao, C., Seiler, C., Pinto, E. M., Matsuoka, L. S., Battig, M. R., Bhoj, E. J. K., Wenger, T. L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0479-2 · Cited by 225
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh, S. J., Rizos, H., Scolyer, R. A., & Long, G. V. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.005 · Cited by 224
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 215
Johnson, D. B., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Kefford, R. F., Hamid, O., Schuchter, L. M., Cebon, J. S., Sharfman, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3535 · Cited by 219
Self-citationKim, G., McKee, A. E., Ning, Y. M., Hazarika, M., Theoret, M. R., Johnson, J. R., Xu, Q. C., Tang, S., Sridhara, R., Jiang, X., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0776 · Cited by 219
ERKs in cancer: friends or foes?
Deschênes-Simard, X., Kottakis, F., Meloche, S., & Ferbeyre, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2381 · Cited by 186
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Hatzivassiliou, G., Liu, B., O'Brien, C. L., Spoerke, J. M., Hoeflich, K. P., Haverty, P. M., Soriano, R. H., Forrest, W. F., Heldens, S., Chen, H., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1010 · Cited by 215
Girotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.006 · Cited by 212
Self-citationTargeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.006 · Cited by 212
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations
Chen, X., Wu, Q., Tan, L., PORTER, D. A., Jager, M. J., Emery, C., & Bastian, B. C. (2013) · Oncogene · doi:10.1038/onc.2013.418 · Cited by 215
Self-citationDrug resistance to targeted therapies: Déjà vu all over again
Groenendijk, F. H., & Bernards, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.004 · Cited by 222
Yadav, V., Zhang, X., Liu, J., Estrem, S., Li, S., Gong, X.-Q., Buchanan, S., Henry, J. R., Starling, J. J., & Peng, S.-B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.377218 · Cited by 200
Targeted Therapy in Melanoma and Mechanisms of Resistance
Czarnecka, A. M., Bartnik, E., Fiedorowicz, M., & Rutkowski, P. L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134576 · Cited by 213
IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase–driven tumors
Jameson, K. L., Mazur, P. K., Zehnder, A. M., Zhang, J., Zarnegar, B. J., Sage, J., & Khavari, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3165 · Cited by 195
Nathanson, K. L., Martin, A., Wubbenhorst, B. S., Greshock, J. D., Letrero, R., D'Andrea, K. P., O'Day, S. J., Infante, J. R., Falchook, G. S., Arkenau, H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0827 · Cited by 200
Anderson, M., Marayati, R., Moffitt, R. A., & Yeh, J. J. (2016) · Oncotarget · doi:10.18632/oncotarget.9760 · Cited by 198
Inhibition of KRAS -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
Zhu, Z., Aref, A. R., Cohoon, T. J., Barbie, T. U., Imamura, Y., Yang, S., Moody, S. E., Shen, R. R., Schinzel, A. C., Thai, T. C., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0646 · Cited by 193
Self-citationChromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers
Kelso, T. W. R., Porter, D. K., Amaral, M. L., Shokhirev, M. N., Benner, C. W., & Hargreaves, D. C. (2017) · eLife · doi:10.7554/elife.30506 · Cited by 199
Systematic identification of signaling pathways with potential to confer anticancer drug resistance
Martz, C. A., Ottina, K. A., Singleton, K. R., Jasper, J. S., Wardell, S. E., Peraza-Penton, A., Anderson, G. R., Winter, P. S., Wang, T., Alley, H. M., et al. (2014) · Science Signaling · doi:10.1126/scisignal.aaa1877 · Cited by 189
Self-citationStark, M. S., Woods, S. L., Gartside, M. G., Bonazzi, V., Dutton‐Regester, K., Aoude, L. G., Chow, D. C., Sereduk, C., Niemi, N. M., Tang, N., et al. (2011) · Nature Genetics · doi:10.1038/ng.1041 · Cited by 189
Uncovering and Dissecting the Genotoxicity of Self-inactivating Lentiviral Vectors In Vivo
Cesana, D., Ranzani, M., Volpin, M., Bartholomae, C., Duros, C., Artus, A., Merella, S., Benedicenti, F., Sergi Sergi, L., Sanvito, F., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.3 · Cited by 189
Villanueva, J., Infante, J. R., Krepler, C., Reyes-Uribe, P. I., Samanta, M., Chen, H., Li, B., Swoboda, R., Wilson, M. A., Vultur, A., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.023 · Cited by 200
Perturbation Biology: Inferring Signaling Networks in Cellular Systems
Molinelli, E. J., Korkut, A., Wang, W., Miller, M. L., Gauthier, N. P., Jing, X., Kaushik, P., He, Q., Mills, G. B., Solit, D. B., et al. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003290 · Cited by 194
New drugs in melanoma: It’s a whole new world
Eggermont, A. M. M., & Robert, C. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.052 · Cited by 185
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Smith, C. C., Paguirigan, A. L., Jeschke, G. R., Lin, K. C., Massi, E., Tarver, T. C., Chin, C.-S., Asthana, S., Olshen, A. B., Travers, K. J., et al. (2017) · Blood · doi:10.1182/blood-2016-04-711820 · Cited by 185
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
Smalley, I., Paraiso, K. H. T., & Smalley, K. S. M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.015 · Cited by 194
Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
Baenke, F., Chaneton, B., Smith, M., van den Broek, N. J. F., Hogan, K., Tang, H., Virós, A., Martin, M. J., Galbraith, L. C. A., Girotti, M. R., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.08.003 · Cited by 191
Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies
Du, W., & Elemento, O. (2014) · Oncogene · doi:10.1038/onc.2014.291 · Cited by 185
Which drug, and when, for patients with BRAF-mutant melanoma?
Jang, S., & Atkins, M. B. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70539-9 · Cited by 182
Principles and Strategies for Developing Network Models in Cancer
Pe’er, D., & Hacohen, N. (2011) · Cell · doi:10.1016/j.cell.2011.03.001 · Cited by 186
Mittapalli, R. K., Vaidhyanathan, S., Dudek, A. Z., & Elmquist, W. F. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201475 · Cited by 182
Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors
Mulcahy Levy, J. M., Zahedi, S., Griesinger, A. M., Morin, A., Davies, K. D., Aisner, D. L., Kleinschmidt-DeMasters, B., Fitzwalter, B. E., Goodall, M. L., Thorburn, J., et al. (2017) · eLife · doi:10.7554/elife.19671 · Cited by 175
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Su, F., Bradley, W. D., Wang, Q., Yang, H. Y., Xu, L., Higgins, B., Kolinsky, K. D., Packman, K. E., Kim, M. J., Trunzer, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1875 · Cited by 180
A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
Wilson, F. H., Johannessen, C. M., Piccioni, F., Tamayo, P., Kim, J. W., Allen, E. M. V., Corsello, S. M., Capelletti, M., Calles, A., Butaney, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.005 · Cited by 178
Self-citationNew Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome
Wilson, L., Linley, A. J., Hammond, D. E., Hood, F. E., Coulson, J. M., MacEwan, D. J., Ross, S. J., Slupsky, J. R., Smith, P. D., Eyers, P. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2291 · Cited by 178
The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Watson, I. R., Li, L., Cabeceiras, P. K., Mahdavi, M., Gutschner, T., Genovese, G., Wang, G., Fang, Z., Tepper, J. M., Stemke‐Hale, K., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1232-t · Cited by 173
Mittapalli, R. K., Vaidhyanathan, S., Sane, R., & Elmquist, W. F. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192195 · Cited by 168
The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms
Paraiso, K. H. T., Haarberg, H. E., Wood, E. R., Rebecca, V. W., Chen, Y. A., Xiang, Y., Ribas, A., Lo, R. S., Weber, J. S., Sondak, V. K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2612 · Cited by 175
Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Villanueva, J., Vultur, A., & Herlyn, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1243 · Cited by 168
Flynn, A. L. B., Calhoun, B. C., Sharma, A., Chang, J. C., Almasan, A., & Schiemann, W. P. (2019) · Nature Communications · doi:10.1038/s41467-019-11640-9 · Cited by 168
Wargo, J. A., Reuben, A., Cooper, Z. A., Oh, K. S., & Sullivan, R. J. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.007 · Cited by 172
Self-citationPAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling
Shrestha, Y., Schafer, E. J., Boehm, J. S., Thomas, S. R., He, F., Du, J., Wang, S., Barretina, J. G., Weir, B. A., Zhao, J. J., et al. (2011) · Oncogene · doi:10.1038/onc.2011.515 · Cited by 166
Self-citationMelanoma: New Insights and New Therapies
Nikolaou, V. A., Stratigos, A., Flaherty, K. T., & Tsao, H. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.421 · Cited by 164
Self-citationMechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 167
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife · doi:10.7554/elife.18970 · Cited by 160
Self-citationMechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma
Lim, S. Y., Menzies, A. M., & Rizos, H. (2017) · Cancer · doi:10.1002/cncr.30435 · Cited by 169
Oocyte DNA damage quality control requires consecutive interplay of CHK2 and CK1 to activate p63
Tuppi, M., Kehrloesser, S., Coutandin, D., Rossi, V., Luh, L. M., Strubel, A., Hötte, K., Hoffmeister, M., Schäfer, B., Oliveira, T. D., et al. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0035-7 · Cited by 166
Small-molecule targeting of brachyury transcription factor addiction in chordoma
Sharifnia, T., Wawer, M. J., Chen, T., Huang, Q., Weir, B. A., Sizemore, A. E., Lawlor, M. A., Goodale, A. B., Cowley, G. S., Vázquez, F., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0312-3 · Cited by 159
Self-citationAP-1/c-Jun transcription factors: Regulation and function in malignant melanoma
Kappelmann‐Fenzl, M., Bosserhoff, A., & Kuphal, S. (2013) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2013.10.003 · Cited by 167
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 166
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
Spagnolo, F., Ghiorzo, P., Orgiano, L., Pastorino, L., Picasso, V., Tornari, E., Ottaviano, V., & Queirolo, P. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s39096 · Cited by 163
Dabrafenib and its potential for the treatment of metastatic melanoma
Murali, R., Menzies, A. M., & Long, G. V. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s38998 · Cited by 165
HEDGEHOG-GLI Signaling Drives Self-Renewal and Tumorigenicity of Human Melanoma-Initiating Cells
Santini, R., Vinci, M. C., Pandolfi, S., Penachioni, J. Y., Montagnani, V., Olivito, B., Gattai, R., Pimpinelli, N., Gerlini, G., Borgognoni, L., et al. (2012) · Stem Cells · doi:10.1002/stem.1160 · Cited by 158
miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma
Díaz‐Martínez, M., Benito-Jardón, L., Alonso, L., Koetz‐Ploch, L., Hernando, E., & Teixidó, J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1318 · Cited by 162
Clinicopathological relevance of BRAF mutations in human cancer
Pakneshan, S., Salajegheh, A., Anthony Smith, R., & King-Yin Lam, A. (2013) · Pathology · doi:10.1097/pat.0b013e328360b61d · Cited by 156
Brady, D. C., Crowe, M. S., Greenberg, D. N., & Counter, C. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1190 · Cited by 159
Fey, D., Halász, M., Dreidax, D., Kennedy, S. P., Hastings, J. F., Rauch, N., Muñoz, A. G., Pilkington, R., Fischer, M., Westermann, F., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab0990 · Cited by 152
Metadata
- Authors
- Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., Caponigro, G., Hieronymus, H., Murray, R. R., Salehi-Ashtiani, K., Hill, D. E., Vidal, M., Zhao, J. J., Yang, X., Alkan, O., Kim, S., Harris, J. L., Wilson, C. J., Myer, V. E., Finan, P. M., Root, D. E., Roberts, T. M., Golub, T., Flaherty, K. T., Dummer, R., Weber, B. L., Sellers, W. R., Schlegel, R., Wargo, J. A., Hahn, W. C., & Garraway, L. A.
- Affiliations
- Broad Institute (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Genomics Institute of the Novartis Research Foundation (US)
- Dana-Farber Cancer Institute (US)
- University of Zurich (CH)
- Corresponding author
- Garraway, Levi A.
- ORCID
- Johannessen, Cory M.
- Boehm, Jesse S.
- Kim, So Young
- Stransky, Nicolas
- Cogdill, Alexandria P.
- Barretina, Jordi
- Hill, David E.
- Vidal, Marc
- Zhao, Jean J.
- Yang, Xiaoping
- Alkan, Ozan
- Wilson, Christopher J.
- Myer, Vic E.
- Root, David E.
- Roberts, Thomas M.
- Golub, Todd
- Flaherty, Keith T.
- Dummer, Reinhard
- Weber, Barbara L.
- Sellers, William R.
- Wargo, Jennifer A.
- Hahn, William C.
- Garraway, Levi A.
- Venue
- Nature
- Published
- 2010-11-24
- Volume
- 468
- Issue
- 7326
- Pages
- 968-972
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3058384
- OpenAlex
- W2141674733
- Cited by
- 1,460
- References
- 30
- Citations by year
- 2026: 19 · 2025: 27 · 2024: 32 · 2023: 55 · 2022: 45 · 2021: 56 · 2020: 67 · 2019: 91 · 2018: 78 · 2017: 102 · 2016: 107 · 2015: 121 · 2014: 158 · 2013: 186 · 2012: 177
- FWCI
- 65.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- National Institutes of Health (DP2OD002750)
- National Cancer Institute (RC2CA148268, R01CA134502, K08CA115927, CA134502, R33CA128625, P50CA093683)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- MAP3K8, BRAF inhibitor resistance, vemurafenib, melanoma, BRAF V600E mutation, MAPK signaling
- MeSH terms
- Vemurafenib, Allosteric Regulation, Clinical Trials as Topic, Enzyme Activation, Humans, Indoles, Melanoma, Proto-Oncogene Proteins, Sulfonamides, Gene Library, Gene Expression Regulation, Neoplastic, Open Reading Frames, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-raf, Gene Expression Profiling, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Kinase Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
